Related Experiment Video
Updated: Aug 23, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
DC therapy for prostate cancer
P W Swindle1, S Tepes, J Clements
1Mater Prostate Cancer Research Centre, Mater Medical Research Institute, Queensland, South Brisbane, Australia.
Abstract:
The wide range of currently available treatments for metastatic prostate cancer have demonstrated a modest palliative effect, but none to date has shown an increase in overall survival. The immune system has evolved to protect against infection, however, the modulation of this system represents the possibility of allowing it to identify and destroy cancer cells. The immune system is capable of inciting a powerful immune response against tissues, in the form of transplant rejection, and the potential exists to harness these powers to fight against tumors. Modest clinical responses have been seen in patients with metastatic prostate cancer treated with DC therapies; however, no increase in overall survival has been demonstrated. The current state of DC immunotherapy for prostate cancer is reviewed.
Insights
Current prostate cancer treatments offer limited survival benefits. Harnessing the immune system, specifically with dendritic cell (DC) therapies, shows potential for cancer cell destruction but has not yet improved overall survival in metastatic prostate cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Metastatic prostate cancer treatments provide modest palliative effects without improving overall survival.
- The immune system can be modulated to target and destroy cancer cells.
- Harnessing immune responses, like those seen in transplant rejection, offers potential for tumor treatment.
Purpose of the Study:
- To review the current state of dendritic cell (DC) immunotherapy for prostate cancer.
- To evaluate the efficacy of DC therapies in metastatic prostate cancer.
- To explore the potential of immune system modulation in prostate cancer treatment.
Main Methods:
- Review of existing clinical data on DC immunotherapy for prostate cancer.
- Analysis of studies investigating immune responses against prostate tumors.
- Assessment of the impact of DC therapies on patient outcomes.
Main Results:
- Modest clinical responses observed in metastatic prostate cancer patients treated with DC therapies.
- No significant increase in overall survival demonstrated with current DC immunotherapy approaches.
- The review highlights the current limitations and potential of DC-based treatments.
Conclusions:
- Dendritic cell (DC) immunotherapy shows promise for treating metastatic prostate cancer by engaging the immune system.
- Despite modest clinical responses, current DC therapies have not yet translated into improved overall survival.
- Further research and development are needed to optimize DC immunotherapy for enhanced efficacy in prostate cancer.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...